Business US
UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers – Business Wire
- UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers Business Wire
- UCB to Buy Candid Therapeutics for Up to $2.2 Billion WSJ
- UCB inks $2B Candid buyout to join Gilead in autoimmune field Fierce Biotech
- UCB to acquire maker of antibody treatments for autoimmune diseases statnews.com
- UCB bets $2B on Candid’s T cell engager ambitions Endpoints News
